Monteris Medical wraps $26.6M Series C financing round

June 2, 2017

The financing will fund investments in R&D, clinical research, and commercial expansion of the NeuroBlate laser ablation system.

BioOptics World Editors

Monteris Medical (Plymouth, MN), which develops minimally invasive, magnetic resonance imaging (MRI)-guided laser ablation systems for treating brain lesions, has completed a Series C financing round, raising $26.6 million in new equity. The company currently markets the NeuroBlate System in the U.S. and Canada as a surgical tool that provides neurosurgeons an alternative to traditional craniotomies.

Related: Monteris Medical presents new data from trials evaluating laser ablation for brain lesions

The Series C financing was led by Versant Ventures and SightLine Partners, with strong participation from current investors Birchview Capital and BDC Capital's Healthcare Venture Fund. The financing will fund significant investments in R&D, clinical research, and commercial expansion.

For more information, please visit www.monteris.com.

About the Author

BioOptics World Editors

We edited the content of this article, which was contributed by outside sources, to fit our style and substance requirements. (Editor’s Note: BioOptics World has folded as a brand and is now part of Laser Focus World, effective in 2022.)